Rapid integrated detection kit for hypersensitivity of influenza virus and monkey pox virus

By designing primer probe sets and optimized detection methods for influenza virus and monkeypox virus, the problem of time-consuming and low sensitivity in the existing technology is solved, and fast and sensitive virus detection is achieved, suitable for high-demand scenarios .

CN118996003APending Publication Date: 2024-11-22BERGER (QINGDAO) MEDICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411185279.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

In the prior art, the detection method of influenza virus and monkeypox virus, Real-time RT-PCR technology takes a long time, has low sensitivity, and is difficult to meet the needs of fast and ultra-sensitive detection, especially in specific scenarios.

Method used

A primer probe set was designed for simultaneously detecting influenza viruses and monkeypox viruses, including primer probe sets for influenza A, B and monkeypox viruses, nucleic acid amplification, combined with specific polymerase combinations and reaction conditions, optimize sample extraction and amplification procedures for rapid detection.

Benefits of technology

It realizes rapid, sensitive and accurate detection of influenza virus and monkeypox virus, shortened the detection time to 30 minutes, increased the sensitivity to ≤50 copies/mL, and the specificity is ≥95%. It is suitable for applications in special scenarios.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005013324360000021
    Figure BDA0005013324360000021
  • Figure BDA0005013324360000031
    Figure BDA0005013324360000031
  • Figure BDA0005013324360000051
    Figure BDA0005013324360000051
Patent Text Reader

Abstract

The invention relates to a method for detecting influenza virus and monkey pox virus. Specifically, the invention discloses a primer set, a kit and a method for simultaneously detecting influenza A virus, influenza B virus and monkey pox virus. The method provided by the invention is rapid, sensitive, high in accuracy and good in result consistency, and can meet the application requirements of special scenes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biological detection, and in particular to an ultra-sensitive rapid integrated detection kit for influenza virus and monkeypox virus. Background Art

[0002] Influenza virus is a common acute respiratory disease with seasonal epidemic or local outbreak characteristics. Among them, influenza A virus often causes influenza pandemics worldwide. The monkeypox virus reported recently also has high infectivity and mortality. For key areas such as entry and exit ports or local outbreaks, the requirements for epidemic prevention are high, so timely, rapid and ultra-sensitive detection of samples to be tested is required.

[0003] Nucleic acid testing is currently the main detection method for influenza virus and monkeypox virus, but conventional Real-time RT-PCR (rRT-PCR) technology is time-consuming, has low sensitivity, and has limitations in specific scenarios with higher requirements.

[0004] Therefore, there is an urgent need in the art for a rapid, ultrasensitive detection kit for influenza virus and monkeypox virus. Summary of the invention

[0005] The purpose of the present invention is to provide a rapid and ultrasensitive detection kit for influenza virus and monkeypox virus.

[0006] In a first aspect of the present invention, a primer probe set for simultaneous detection of influenza virus and monkeypox virus, the primer set comprising:

[0007] (a) A primer probe set for influenza A virus, comprising:

[0008] An upstream primer having a nucleotide sequence as shown in SEQ ID NO: 1, a downstream primer having a nucleotide sequence as shown in SEQ ID NO: 2, and a probe having a nucleotide sequence as shown in SEQ ID NO: 3;

[0009] (b) A primer probe set for influenza B virus, comprising:

[0010] an upstream primer having a nucleotide sequence as shown in SEQ ID NO: 4, a downstream primer having a nucleotide sequence as shown in SEQ ID NO: 5, and a probe having a nucleotide sequence as shown in SEQ ID NO: 6; and

[0011] (c) A primer probe set for monkeypox virus, comprising:

[0012] An upstream primer having a nucleotide sequence as shown in SEQ ID NO:7, a downstream primer having a nucleotide sequence as shown in SEQ ID NO:8, and a probe having a nucleotide sequence as shown in SEQ ID NO:9.

[0013] In another preferred embodiment, the primer probe set for influenza A virus is selected from the following group:

[0014] (a1) an upstream primer having a nucleotide sequence as shown in SEQ ID NO: 1, a downstream primer having a nucleotide sequence as shown in SEQ ID NO: 2, and a probe having a nucleotide sequence as shown in SEQ ID NO: 3;

[0015] (a2) an upstream primer having a nucleotide sequence as shown in SEQ ID NO: 13, a downstream primer having a nucleotide sequence as shown in SEQ ID NO: 14, and a probe having a nucleotide sequence as shown in SEQ ID NO: 15;

[0016] (a3) an upstream primer having the nucleotide sequence shown in SEQ ID NO:16, a downstream primer having the nucleotide sequence shown in SEQ ID NO:17, and a probe having the nucleotide sequence shown in SEQ ID NO:18.

[0017] In another preferred embodiment, the probe has phosphorylated nucleotides.

[0018] In another preferred embodiment, the probe has a fluorescent group and a quenching group.

[0019] In another preferred embodiment, one or more nucleotides in the upstream primer and the downstream primer are replaced by locked nucleic acid.

[0020] In another preferred embodiment, the fluorescent group is selected from the following group: FAM, Cy3, Cy5, VIC, HEX, JOE, TAMRA, ROX, TET, NED, or a combination thereof.

[0021] In another preferred embodiment, the quenching group is selected from the following group: MGB, BHQ1, BHQ2, BHQ3, TAMRA, or a combination thereof.

[0022] In another preferred embodiment, the phosphorylated nucleotides are located at the 1st to 3rd positions at the 3' end of the probe.

[0023] In another preferred embodiment, the fluorescent group is modified on the nucleotides at positions 1 to 5, preferably positions 2 to 5, and more preferably positions 3 to 5, at the 5' end of the probe.

[0024] In another preferred embodiment, the quencher group is modified on the nucleotides at positions 1 to 5 at the 3' end of the probe, preferably at positions 2 to 5, and more preferably at positions 3 to 5.

[0025] In another preferred embodiment, the probe has only one phosphorylated nucleotide.

[0026] In another preferred embodiment, one nucleotide in the upstream primer and the downstream primer is replaced by a locked nucleic acid.

[0027] In another preferred embodiment, the locked nucleic acid replaces the nucleotide corresponding to guanine.

[0028] In another preferred embodiment, the locked nucleic acid replaces the nucleotide corresponding to cytosine.

[0029] In another preferred example, the primer-probe set also includes primers and probes for internal references, preferably, an upstream primer having a nucleotide sequence as shown in SEQ ID NO: 10, a downstream primer having a nucleotide sequence as shown in SEQ ID NO: 11, and a probe having a nucleotide sequence as shown in SEQ ID NO: 12.

[0030] In another preferred embodiment, the primer probe set includes

[0031]

[0032]

[0033] In a second aspect, the present invention provides the use of the primer probe set as described in the first aspect of the present invention for preparing a detection reagent or a kit for detecting a virus.

[0034] In another preferred embodiment, the virus is selected from the following group: influenza A virus, influenza B virus, or a combination thereof.

[0035] In a third aspect, the present invention provides a kit, comprising (i) a container and (ii) the primer-probe set according to the first aspect of the present invention.

[0036] In another preferred example, the kit further comprises a polymerase, and the polymerase is selected from the following group: Taq enzyme, Vent enzyme, Tth enzyme, or a combination thereof.

[0037] In another preferred embodiment, the polymerase is in the form of freeze-dried microspheres.

[0038] In another preferred embodiment, the enzyme activity ratio of Taq enzyme, Vent enzyme and Tth enzyme in the polymerase is: 1-10:0.1-5:1-5, preferably 1-5:0.2-3:1-3, and more preferably 1-3:0.5-1:1-2.

[0039] In another preferred embodiment, the kit further comprises proteinase K.

[0040] In another preferred embodiment, the test kit further comprises a sampling dry swab set, wherein the dry swab set comprises a swab head and a swab trunk, and the swab head and the swab trunk have only two connection points.

[0041] In another preferred embodiment, the kit further comprises reagents required for nucleic acid amplification reaction, and preferably the nucleic acid amplification reaction is conventional PCR or real-time fluorescence PCR or digital PCR.

[0042] In another preferred embodiment, the reagents required for the nucleic acid amplification reaction include Mg 2+ , deoxyribonucleotide triphosphate.

[0043] In a fourth aspect, the present invention provides a method for simultaneously detecting influenza virus and monkeypox virus, the method comprising the following steps:

[0044] (s1) providing a sample to be tested, a primer probe set as described in the first aspect of the present invention, and a polymerase;

[0045] (s2) Under conditions suitable for amplification, the primer probe set is used to perform nucleic acid amplification on the sample to be tested, and then the test is performed to obtain a test result.

[0046] In another preferred embodiment, the sample to be tested is treated with proteinase K.

[0047] In another preferred embodiment, the influenza virus is selected from the following group: influenza A virus, influenza B virus, or a combination thereof.

[0048] In another preferred embodiment, the primer probe set is used to perform nucleic acid amplification on the sample to be tested under the action of polymerase, and then the test is performed to obtain the test result.

[0049] In another preferred example, the polymerase is selected from the following group: Taq enzyme, Vent enzyme, Tth enzyme, or a combination thereof.

[0050] In another preferred embodiment, the polymerase is in the form of freeze-dried microspheres.

[0051] In another preferred embodiment, the enzyme activity ratio of Taq enzyme, Vent enzyme and Tth enzyme in the polymerase is: 1-10:0.1-5:1-5, preferably 1-5:0.2-3:1-3, and more preferably 1-3:0.5-1:1-2.

[0052] In another preferred example, the detection includes detecting a fluorescence signal.

[0053] In another preferred example, the nucleic acid amplification is selected from the following group: PCR, qPCR, digital PCR, nucleic acid isothermal amplification, RT-PCR, or a combination thereof.

[0054] In another preferred embodiment, the reaction conditions for the amplification are: 50°C, 5 minutes, 1 cycle; 97°C, 1 minute, 1 cycle; 97°C, 5 seconds, 60°C, 10 seconds, 40 cycles.

[0055] In another preferred embodiment, the sensitivity of the method is ≤100 copies / mL, preferably ≤75 copies / mL, and more preferably ≤50 copies / mL.

[0056] In another preferred embodiment, the specificity of the method is ≥95%, preferably ≥96%, and more preferably ≥98%.

[0057] In another preferred embodiment, the sensitivity of the method is ≥80%, preferably ≥90%, and more preferably ≥95%.

[0058] In another preferred embodiment, the method is non-therapeutic and non-diagnostic.

[0059] In another preferred embodiment, the method is in vitro.

[0060] In a fifth aspect, the present invention provides a primer probe set for detecting influenza A virus, comprising:

[0061] (a1) an upstream primer having a nucleotide sequence as shown in SEQ ID NO: 1, a downstream primer having a nucleotide sequence as shown in SEQ ID NO: 2, and a probe having a nucleotide sequence as shown in SEQ ID NO: 3;

[0062] (a2) an upstream primer having a nucleotide sequence as shown in SEQ ID NO: 13, a downstream primer having a nucleotide sequence as shown in SEQ ID NO: 14, and a probe having a nucleotide sequence as shown in SEQ ID NO: 15;

[0063] (a3) an upstream primer having the nucleotide sequence shown in SEQ ID NO:16, a downstream primer having the nucleotide sequence shown in SEQ ID NO:17, and a probe having the nucleotide sequence shown in SEQ ID NO:18.

[0064] In another preferred example, the primer-probe set also includes primers and probes for internal references, preferably, an upstream primer having a nucleotide sequence as shown in SEQ ID NO: 10, a downstream primer having a nucleotide sequence as shown in SEQ ID NO: 11, and a probe having a nucleotide sequence as shown in SEQ ID NO: 12.

[0065] In another preferred embodiment, the probe has phosphorylated nucleotides.

[0066] In another preferred embodiment, the probe has a fluorescent group and a quenching group.

[0067] In another preferred embodiment, one or more nucleotides in the upstream primer and the downstream primer are replaced by locked nucleic acid.

[0068] In another preferred embodiment, the fluorescent group is selected from the following group: FAM, Cy3, Cy5, VIC, HEX, JOE, TAMRA, ROX, TET, NED, or a combination thereof.

[0069] In another preferred embodiment, the quenching group is selected from the following group: MGB, BHQ1, BHQ2, BHQ3, TAMRA, or a combination thereof.

[0070] In another preferred embodiment, the phosphorylated nucleotides are located at the 1st to 3rd positions at the 3' end of the probe.

[0071] In another preferred embodiment, the fluorescent group is modified on the nucleotides at positions 1 to 5, preferably positions 2 to 5, and more preferably positions 3 to 5, at the 5' end of the probe.

[0072] In another preferred embodiment, the quencher group is modified on the nucleotides at positions 1 to 5 at the 3' end of the probe, preferably at positions 2 to 5, and more preferably at positions 3 to 5.

[0073] In another preferred embodiment, the probe has only one phosphorylated nucleotide.

[0074] In another preferred embodiment, one nucleotide in the upstream primer and the downstream primer is replaced by a locked nucleic acid.

[0075] In another preferred embodiment, the locked nucleic acid replaces the nucleotide corresponding to guanine.

[0076] In another preferred embodiment, the locked nucleic acid replaces the nucleotide corresponding to cytosine.

[0077] In another preferred embodiment, the primer probe set comprises:

[0078]

[0079] In another preferred embodiment, the primer probe set is used to prepare a detection reagent or a kit for detecting influenza A virus.

[0080] In a sixth aspect, the present invention provides a primer probe set for detecting influenza B virus, comprising:

[0081] An upstream primer having a nucleotide sequence as shown in SEQ ID NO:4, a downstream primer having a nucleotide sequence as shown in SEQ ID NO:5, and a probe having a nucleotide sequence as shown in SEQ ID NO:6.

[0082] In another preferred example, the primer-probe set also includes primers and probes for internal references, preferably, an upstream primer having a nucleotide sequence as shown in SEQ ID NO: 10, a downstream primer having a nucleotide sequence as shown in SEQ ID NO: 11, and a probe having a nucleotide sequence as shown in SEQ ID NO: 12.

[0083] In another preferred embodiment, the probe has phosphorylated nucleotides.

[0084] In another preferred embodiment, the probe has a fluorescent group and a quenching group.

[0085] In another preferred embodiment, one or more nucleotides in the upstream primer and the downstream primer are replaced by locked nucleic acid.

[0086] In another preferred embodiment, the fluorescent group is selected from the following group: FAM, Cy3, Cy5, VIC, HEX, JOE, TAMRA, ROX, TET, NED, or a combination thereof.

[0087] In another preferred embodiment, the quenching group is selected from the following group: MGB, BHQ1, BHQ2, BHQ3, TAMRA, or a combination thereof.

[0088] In another preferred embodiment, the phosphorylated nucleotides are located at the 1st to 3rd positions at the 3' end of the probe.

[0089] In another preferred embodiment, the fluorescent group is modified on the nucleotides at positions 1 to 5, preferably positions 2 to 5, and more preferably positions 3 to 5, at the 5' end of the probe.

[0090] In another preferred embodiment, the quencher group is modified on the nucleotides at positions 1 to 5 at the 3' end of the probe, preferably at positions 2 to 5, and more preferably at positions 3 to 5.

[0091] In another preferred embodiment, the probe has only one phosphorylated nucleotide.

[0092] In another preferred embodiment, one nucleotide in the upstream primer and the downstream primer is replaced by a locked nucleic acid.

[0093] In another preferred embodiment, the locked nucleic acid replaces the nucleotide corresponding to guanine.

[0094] In another preferred embodiment, the locked nucleic acid replaces the nucleotide corresponding to cytosine.

[0095] In another preferred embodiment, the primer probe set comprises:

[0096]

[0097] In another preferred embodiment, the primer probe set is used to prepare a detection reagent or a kit for detecting influenza B virus.

[0098] The seventh aspect of the present invention provides a primer probe set for detecting monkeypox virus, comprising

[0099] An upstream primer having a nucleotide sequence as shown in SEQ ID NO:7, a downstream primer having a nucleotide sequence as shown in SEQ ID NO:8, and a probe having a nucleotide sequence as shown in SEQ ID NO:9.

[0100] In another preferred example, the primer-probe set also includes primers and probes for internal references, preferably, an upstream primer having a nucleotide sequence as shown in SEQ ID NO: 10, a downstream primer having a nucleotide sequence as shown in SEQ ID NO: 11, and a probe having a nucleotide sequence as shown in SEQ ID NO: 12.

[0101] In another preferred embodiment, the probe has phosphorylated nucleotides.

[0102] In another preferred embodiment, the probe has a fluorescent group and a quenching group.

[0103] In another preferred embodiment, one or more nucleotides in the upstream primer and the downstream primer are replaced by locked nucleic acid.

[0104] In another preferred embodiment, the fluorescent group is selected from the following group: FAM, Cy3, Cy5, VIC, HEX, JOE, TAMRA, ROX, TET, NED, or a combination thereof.

[0105] In another preferred embodiment, the quenching group is selected from the following group: MGB, BHQ1, BHQ2, BHQ3, TAMRA, or a combination thereof.

[0106] In another preferred embodiment, the phosphorylated nucleotides are located at the 1st to 3rd positions at the 3' end of the probe.

[0107] In another preferred embodiment, the fluorescent group is modified on the nucleotides at positions 1 to 5, preferably positions 2 to 5, and more preferably positions 3 to 5, at the 5' end of the probe.

[0108] In another preferred embodiment, the quencher group is modified on the nucleotides at positions 1 to 5 at the 3' end of the probe, preferably at positions 2 to 5, and more preferably at positions 3 to 5.

[0109] In another preferred embodiment, the probe has only one phosphorylated nucleotide.

[0110] In another preferred embodiment, one nucleotide in the upstream primer and the downstream primer is replaced by a locked nucleic acid.

[0111] In another preferred embodiment, the locked nucleic acid replaces the nucleotide corresponding to guanine.

[0112] In another preferred embodiment, the locked nucleic acid replaces the nucleotide corresponding to cytosine.

[0113] In another preferred embodiment, the primer probe set comprises:

[0114]

[0115] In another preferred embodiment, the primer probe set is used to prepare a detection reagent or kit for detecting monkeypox virus.

[0116] In an eighth aspect, the present invention provides a method for detecting a virus, comprising the steps of:

[0117] (s1) providing a sample to be tested, a primer probe set as described in the fifth aspect, the sixth aspect, or the seventh aspect of the present invention, and a polymerase;

[0118] (s2) Under conditions suitable for amplification, the primer probe set is used to perform nucleic acid amplification on the sample to be tested, and then the test is performed to obtain a test result.

[0119] In another preferred embodiment, the virus is selected from the group consisting of influenza A virus, influenza B virus, or monkeypox virus.

[0120] In another preferred embodiment, the sample to be tested is treated with proteinase K.

[0121] In another preferred embodiment, the primer probe set is used to perform nucleic acid amplification on the sample to be tested under the action of polymerase, and then the test is performed to obtain the test result.

[0122] In another preferred example, the polymerase is selected from the following group: Taq enzyme, Vent enzyme, Tth enzyme, or a combination thereof.

[0123] In another preferred embodiment, the polymerase is in the form of freeze-dried microspheres.

[0124] In another preferred embodiment, the enzyme activity ratio of Taq enzyme, Vent enzyme and Tth enzyme in the polymerase is: 1-10:0.1-5:1-5, preferably 1-5:0.2-3:1-3, and more preferably 1-3:0.5-1:1-2.

[0125] In another preferred example, the detection includes detecting a fluorescence signal.

[0126] In another preferred example, the nucleic acid amplification is selected from the following group: PCR, qPCR, digital PCR, nucleic acid isothermal amplification, RT-PCR, or a combination thereof.

[0127] In another preferred embodiment, the reaction conditions for the amplification are: 50°C, 5 minutes, 1 cycle; 97°C, 1 minute, 1 cycle; 97°C, 5 seconds, 60°C, 10 seconds, 40 cycles.

[0128] In another preferred embodiment, the sensitivity of the method is ≤100 copies / mL, preferably ≤75 copies / mL, and more preferably ≤50 copies / mL.

[0129] In another preferred embodiment, the specificity of the method is ≥95%, preferably ≥96%, and more preferably ≥98%.

[0130] In another preferred embodiment, the sensitivity of the method is ≥80%, preferably ≥90%, and more preferably ≥95%.

[0131] In another preferred embodiment, the method is non-therapeutic and non-diagnostic.

[0132] In another preferred embodiment, the method is in vitro.

[0133] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0134] Figure 1 A special sampling dry swab kit is shown.

[0135] Figure 2 A graph showing the qPCR results of different nucleic acid extraction methods, targeting influenza A virus.

[0136] Figure 3 A comparison of the detection results of different locked nucleic acid modifications is shown.

[0137] Figure 4 The results of the detection of different combinations of modification modes are shown.

[0138] Figure 5 A comparison of different DNA polymerase combinations is shown.

[0139] Figure 6 A comparison of the specificity and specificity of different reaction procedures is shown.

[0140] Figure 7 The real sample detection results are shown. DETAILED DESCRIPTION

[0141] After extensive and in-depth research, a large number of experiments and screening, the inventors have discovered for the first time a primer set and a kit for simultaneously detecting influenza A virus, influenza B virus and monkeypox virus. The inventors designed multiple primers for the conserved regions of influenza A virus, influenza B virus and monkeypox virus and modified the primers to improve their functions, and obtained the primer probe set of the present invention after experimental screening. The inventors also optimized the nucleic acid extraction method, polymerase combination, and nucleic acid amplification procedure, and finally obtained the best detection system and detection conditions. The method for detecting influenza A virus, influenza B virus and monkeypox virus using the primer set and kit of the present invention is fast, sensitive, highly accurate, and has good consistency of results.

[0142] The inventor optimized the relevant technologies. In addition to designing primer probes in relatively conservative regions of traditional pathogens, the inventor also selected special modifications to improve the detection effect. The inventor also optimized the sample extraction and enrichment method to effectively extract even a small amount of samples. The inventor also applied freeze-drying technology to greatly increase the sample loading amount and achieve the effect of ultra-sensitive detection. The inventor also optimized the reaction procedure to complete the amplification in 30 minutes, meeting the application requirements of special scenarios. The inventor completed the present invention on this basis.

[0143] the term

[0144] In order to more easily understand the present invention, some technical and scientific terms are specifically defined below. Unless otherwise clearly defined in this article, all other technical and scientific terms used herein have the meanings commonly understood by those of ordinary skill in the art to which the present invention belongs. Before describing the present invention, it should be understood that the present invention is not limited to the specific methods and experimental conditions, because such methods and conditions can be changed. It should also be understood that the terms used herein are intended only to describe specific embodiments, and are not intended to be restrictive, and the scope of the present invention will be limited only by the appended claims.

[0145] As used herein, the term “comprise” or variations thereof such as “include” or “comprising”, etc., are understood to include the stated elements or components but do not exclude other elements or components.

[0146] The term "about" can refer to a value or composition that is within an acceptable error range for a particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined. For example, as used herein, the expression "about 100" includes all values ​​between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0147] As used herein, unless otherwise indicated, any concentration range, percentage range, ratio range or integer range should be understood to include any integer value within the range and fractional values ​​thereof (e.g., one tenth and one hundredth of an integer) where appropriate.

[0148] As used herein, the term "and / or" refers to and encompasses any and all possible combinations of one or more of the associated listed items.

[0149] Influenza virus

[0150] Influenza virus is called influenza virus for short. It is divided into three types: A, B, and C. Influenza viruses discovered in recent years are classified as D. Human influenza is mainly caused by influenza A virus and influenza B virus. Among them, influenza A virus antigenically mutates easily and has caused global pandemics many times. Influenza A virus often undergoes antigenic mutation and can be further divided into subtypes such as H1N1, H3N2, H5N1, and H7N9 (where H and N represent two surface glycoproteins of influenza virus, respectively).

[0151] The present invention uses the M gene of influenza A virus as a target (gene accession number: PP265109).

[0152] The present invention uses the NEP gene of influenza B virus as a target (gene accession number: PP920997).

[0153] Monkeypox virus

[0154] Monkeypox virus is a poxvirus, belonging to the same genus as smallpox virus, orthopoxvirus, and there are two types. Monkeypox is mainly prevalent in the tropical rainforests of Central and West Africa, and broke out in countries outside Africa in 2003.

[0155] Monkeypox virus (MPXV) belongs to the genus Orthopoxvirus of the Poxviridae family. It is a double-stranded DNA virus with a genome length of about 197kb. The virus can cause monkeypox in humans and animals. Monkeypox virus mainly invades the human body through mucous membranes and broken skin. It is mainly transmitted through direct contact with the diseased skin or mucous membranes of the case, and can also be transmitted through contact with virus-contaminated objects, long-term close inhalation of respiratory droplets of the case, contact with respiratory secretions, lesion exudates, blood and other body fluids of infected animals, or infection and transmission through bites and scratches of infected animals.

[0156] The present invention uses the OPG065 gene of monkeypox virus as a target (gene accession number: OQ729808).

[0157] Primer probe set of the present invention

[0158] The primer probe set of the present invention comprises:

[0159] (a) A primer probe set for influenza A virus, comprising:

[0160] An upstream primer having a nucleotide sequence as shown in SEQ ID NO: 1, a downstream primer having a nucleotide sequence as shown in SEQ ID NO: 2, and a probe having a nucleotide sequence as shown in SEQ ID NO: 3;

[0161] (b) A primer probe set for influenza B virus, comprising:

[0162] an upstream primer having a nucleotide sequence as shown in SEQ ID NO: 4, a downstream primer having a nucleotide sequence as shown in SEQ ID NO: 5, and a probe having a nucleotide sequence as shown in SEQ ID NO: 6; and

[0163] (c) A primer probe set for monkeypox virus, comprising:

[0164] An upstream primer having a nucleotide sequence as shown in SEQ ID NO:7, a downstream primer having a nucleotide sequence as shown in SEQ ID NO:8, and a probe having a nucleotide sequence as shown in SEQ ID NO:9.

[0165] In a preferred embodiment, the probe has phosphorylated nucleotides.

[0166] In a preferred embodiment, the probe has a fluorescent group and a quenching group.

[0167] In a preferred embodiment, one or more nucleotides of the upstream primer and the downstream primer are replaced by locked nucleic acid.

[0168] In a preferred embodiment, the fluorescent group is selected from the group consisting of FAM, Cy3, Cy5, VIC, HEX, JOE, TAMRA, ROX, TET, NED, or a combination thereof. In a preferred embodiment, the quenching group is selected from the group consisting of MGB, BHQ1, BHQ2, BHQ3, TAMRA, or a combination thereof.

[0169] In a preferred embodiment, the primer-probe set also includes primers and probes for internal references, preferably, an upstream primer having a nucleotide sequence as shown in SEQ ID NO: 10, a downstream primer having a nucleotide sequence as shown in SEQ ID NO: 11, and a probe having a nucleotide sequence as shown in SEQ ID NO: 12.

[0170] In a preferred embodiment, the primer set comprises

[0171]

[0172]

[0173] The primers in the primer probe set of the present invention are modified with locked nucleic acid, which makes the primers more stable; the probes are phosphorylated, which can improve the detection efficiency.

[0174] In a preferred embodiment, the primer probe set of the present invention only includes a primer probe set for influenza A virus, and can be used to detect influenza A virus alone, and can be used to prepare a detection reagent or kit for detecting influenza A virus.

[0175] In a preferred embodiment, the primer probe set of the present invention only includes a primer probe set for influenza B virus, which can be used to detect influenza B virus alone, and can be used to prepare a detection reagent or kit for detecting influenza B virus.

[0176] In a preferred embodiment, the primer probe set of the present invention only includes a primer probe set for monkeypox influenza virus, which can be used to detect monkeypox virus alone, and can be used to prepare a detection reagent or kit for detecting monkeypox virus.

[0177] Kit of the present invention

[0178] The kit of the present invention comprises (i) a container and (ii) the primer-probe set of the present invention.

[0179] In a preferred embodiment, the kit further comprises a polymerase selected from the group consisting of Taq enzyme, Vent enzyme, Tth enzyme, or a combination thereof. In a preferred embodiment, the enzyme activity ratio of the Taq enzyme, Vent enzyme, and Tth enzyme is 1 to 3:0.1 to 1:1 to 2. When the enzyme activity ratio of the Taq enzyme, Vent enzyme, and Tth enzyme is 3:0.5:1.5, the amplification effect is the best and the specificity is the best.

[0180] In a preferred embodiment, the polymerase is in the form of lyophilized microspheres.

[0181] In a preferred embodiment, the kit also includes a sampling dry swab set. When using the dry swab set to collect samples, the swab head is easy to peel off, which is convenient for processing the collected samples, can maximize the acquisition of all nucleic acids, and avoid the randomness of low-content sample extraction.

[0182] In a preferred embodiment, the kit further comprises proteinase K. After being treated with proteinase K, the release and cleavage of the sample can be increased, thereby obtaining a high-concentration nucleic acid sample.

[0183] In a preferred embodiment, the kit further comprises reagents required for nucleic acid amplification reaction.

[0184] Detection method of the present invention

[0185] The detection method of the present invention comprises the steps of:

[0186] (s1) providing a sample to be tested, a primer probe set of the present invention and a polymerase;

[0187] (s2) Under conditions suitable for amplification, the primer probe set is used to perform nucleic acid amplification on the sample to be tested, and then the test is performed to obtain a test result.

[0188] In a preferred embodiment, the method can detect influenza A virus, influenza B virus and monkeypox virus individually, or can detect influenza A virus, influenza B virus and monkeypox virus simultaneously.

[0189] In a preferred embodiment, the primer probe set is used to perform nucleic acid amplification on the sample to be tested under the action of polymerase, and then the test is performed to obtain the test result.

[0190] In a preferred embodiment, the detecting comprises detecting a fluorescent signal.

[0191] In a preferred embodiment, the nucleic acid amplification is selected from the group consisting of PCR, qPCR, digital PCR, nucleic acid isothermal amplification, RT-PCR, or a combination thereof.

[0192] In a preferred embodiment, the sensitivity of the method is ≤100 copies / mL, preferably ≤75 copies / mL, and more preferably ≤50 copies / mL.

[0193] In a preferred embodiment, the specificity of the method is ≥95%, preferably ≥96%, and more preferably ≥98%.

[0194] In a preferred embodiment, the sensitivity of the method is ≥80%, preferably ≥90%, and more preferably ≥95%.

[0195] The main advantages of the present invention include:

[0196] 1. The kit of the present invention can simultaneously detect influenza A virus, influenza B virus and monkeypox virus.

[0197] 2. The primers of the present invention are modified with locked nucleic acids to make the primers more stable, and the probes are provided with phosphorylated nucleotides, fluorescent groups and quenching groups, so that the detection method using the primer and probe set of the present invention has good specificity and high sensitivity.

[0198] 3. The method of the present invention takes a short time to detect, and the detection can be completed in 30 minutes.

[0199] 4. The method of the present invention has good result stability and multiple application scenarios.

[0200] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.

[0201] General method of the present invention

[0202] 1. Use a special dry swab sampling kit for sampling;

[0203] 2. Peel off the dry swab head, put it into the nucleic acid extraction reagent, and add 20ul of proteinase K;

[0204] 3. Thaw the reagent kit at room temperature, shake thoroughly and mix thoroughly, then centrifuge immediately;

[0205] 4. Take out the pre-packed freeze-dried eight-tube, add 25ul of the sample to be tested and the positive and negative controls, cover the tube tightly, shake evenly and centrifuge instantly;

[0206] 5. Place the PCR reaction tube in a fluorescent quantitative PCR instrument for amplification and fluorescent signal detection;

[0207] 6. The reaction conditions of the amplification reaction were: 50°C, 5 minutes, 1 cycle; 97°C, 1 minute, 1 cycle; 97°C, 5 seconds, 60°C, 10 seconds, 40 cycles;

[0208] 7. Determine the sample test results.

[0209] The samples to be tested in Examples 2 to 8 were standard samples, the negative control was saline, and the positive control was a sample with a copy number of 10. 6 The corresponding pseudovirus.

[0210] Example 1 Special Sampling Dry Swab Set

[0211] This embodiment uses a special sampling dry swab set ( Figure 1 ), the swab head and the swab trunk have only two bonding points, which facilitates the peeling of the swab head.

[0212] Example 2 Comparison of the products extracted by the conventional nucleic acid extraction method and the optimized nucleic acid extraction method

[0213] 2.1 Methods

[0214] The traditional nucleic acid extraction method dilutes the sample with a preservation solution and only takes a part of it for nucleic acid extraction. The obtained nucleic acid product is a small part of the entire sample and has a low nucleic acid content. The optimized nucleic acid extraction method uses the special sampling dry swab kit described in Example 1 to collect the sample. The swab head can be directly peeled off, so that the entire sample can be extracted. The obtained nucleic acid product is the entire sample and has a high nucleic acid content.

[0215] The product of the conventional nucleic acid extraction using 200ul of diluent was compared with the product of directly inserting the stripped swab head into the nucleic acid extraction reagent (with or without proteinase K 10mg / ml).

[0216] 2.2 Results

[0217] like Figure 2 As shown, combination 1: traditional nucleic acid extraction; combination 2: optimized nucleic acid extraction (without proteinase K); combination 3: optimized nucleic acid extraction (with proteinase K). The results show that the optimized extraction method and the addition of proteinase K have the best effect.

[0218] Traditional nucleic acid extraction only takes part of the sample, and the nucleic acid content obtained is relatively low; the nucleic acid extraction after the optimized method processes the entire sample, and theoretically obtains all the nucleic acids of the entire sample. For the optimized nucleic acid extraction method, all nucleic acids can be obtained to the maximum extent, avoiding the randomness of low-content sample extraction. And by adding proteinase K treatment, the release and cleavage of the sample are increased, so that the sample nucleic acid is obtained more fully.

[0219] Example 3 Primer screening experiment

[0220] 3.1 Methods

[0221] Primer screening experiments were performed using the primers listed in Table 1. 50 influenza A samples (real samples: throat swabs) were used as templates.

[0222] Table 1

[0223]

[0224] 3.2 Results

[0225] The statistical results of the detection rates of 50 influenza A samples were as follows: combination 1 (90%), combination 2 (98%), and combination 3 (100%). Finally, group 3 primers were selected.

[0226] Example 4 Screening of different modified positions of locked nucleic acid

[0227] 4.1 Methods

[0228] The primer probe set screened in Example 3 was selected to optimize the modification position of the locked nucleic acid. The primers and locked nucleic acid modifications used in this example are shown in Table 2.

[0229] Table 2

[0230]

[0231]

[0232] 4.2 Results

[0233] The results are as follows Figure 3 As shown in the figure, the modified positions of the locked nucleic acid in the primers are different, which significantly affects the amplification efficiency. When the locked nucleic acid is modified at the base G, the CT value of the amplification curve is advanced, and the detection efficiency is improved.

[0234] Example 5 Screening of different primer-probe modification combinations

[0235] 5.1 Methods

[0236] The primers used in this example are shown in Table 3, and the method described in the general method was used.

[0237] Table 3

[0238]

[0239]

[0240] 5.2 Results

[0241] The detection results of different modification methods are as follows Figure 4 As shown in Table 4, the amplification effect of modification 3 is better than that of modifications 1 and 2. After the locked nucleic acid in the primer is modified, the TM value becomes higher, which improves the amplification efficiency of the system. At the same time, the probe is phosphorylated and modified, the background signal value is low, and the detection signal value (fluorescence signal intensity) is improved.

[0242] Table 4

[0243]

[0244]

[0245] Example 6 Different DNA polymerase combinations

[0246] 6.1 Methods

[0247] The best DNA polymerase combination was explored with three different DNA polymerase combinations, combination 1 (2U Taq enzyme), combination 2 (2U Taq enzyme + 0.5U Vent enzyme), combination 3 (2U Taq enzyme + 0.5U Vent enzyme + 1.5U Tth enzyme). The experimental steps were the same as those described in the general method.

[0248] 6.2 Results

[0249] Test results such as Figure 5 As shown, combination 3 has the best amplification effect and the highest specificity.

[0250] Example 7 Optimization of reaction procedure

[0251] 7.1 Methods

[0252] This example adopts the method described in the general method, and adopts 3 reaction procedures respectively, as shown in Table 5:

[0253] Table 5

[0254]

[0255] The heating and cooling rate in each program was 3.66℃ / s.

[0256] 7.2 Results

[0257] The results are as follows Figure 6 As shown in the figure, with the increase of denaturation temperature and annealing temperature, the detection performance of the kit is significantly improved in terms of repeatability and low concentration detection. The denaturation temperature of 97°C is the best adaptation temperature for the system, and the annealing temperature of 60°C is the best adaptation temperature for the primer probe.

[0258] Example 8 Specificity and sensitivity of the method of the present invention

[0259] 8.1 Methods

[0260] This example uses modification 3 in Example 4 to detect the specificity and sensitivity of the method of the present invention. The sample for specificity detection is a negative sample, and the sample for sensitivity detection (detection rate experiment) is a positive sample (pseudovirus).

[0261] 8.2 Results

[0262] The results are shown in Table 6. With the increase of denaturation temperature and annealing temperature, the specificity of the kit was optimal and the detection rate was the highest under the detection of program 3.

[0263] Table 6

[0264]

[0265] Example 9 Actual sample detection experiment

[0266] 9.1 Methods

[0267] This example uses samples 1 to 5 to test the effect of the method of the present invention in practical applications. Samples 1, 2 and 3 are influenza A samples, and samples 4 and 5 are influenza B samples.

[0268] 9.2 Results

[0269] Table 7

[0270] Target Test results (CT value) Sample 1 FLUA:23.96; RNaseP:33.04 Sample 2 FLUA:25.04; RNaseP:26.57 Sample 3 FLUA:33.82; RNaseP:32.41 Sample 4 FLUB:36.19; RNaseP:36.52 Sample 5 FLUB:27.64; RNaseP:33.30

[0271] The results are shown in Table 7 and Figure 7 (Influenza A is blue; Influenza B is green; internal reference is purple) as shown, it can be detected in real samples of different sample types.

[0272] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A primer probe set for simultaneous detection of influenza virus and monkeypox virus, characterized in that: The primer set includes: (a) A primer probe set for influenza A virus, comprising: An upstream primer having a nucleotide sequence as shown in SEQ ID NO: 1, a downstream primer having a nucleotide sequence as shown in SEQ ID NO: 2, and a probe having a nucleotide sequence as shown in SEQ ID NO: 3; (b) A primer probe set for influenza B virus, comprising: an upstream primer having a nucleotide sequence as shown in SEQ ID NO: 4, a downstream primer having a nucleotide sequence as shown in SEQ ID NO: 5, and a probe having a nucleotide sequence as shown in SEQ ID NO: 6; and (c) A primer probe set for monkeypox virus, comprising: An upstream primer having a nucleotide sequence as shown in SEQ ID NO:7, a downstream primer having a nucleotide sequence as shown in SEQ ID NO:8, and a probe having a nucleotide sequence as shown in SEQ ID NO:

9.

2. The primer-probe set according to claim 1, characterized in that: The probe has phosphorylated nucleotides.

3. The primer-probe set according to claim 1, characterized in that: The probe comprises a fluorescent group and a quenching group.

4. The primer-probe set according to claim 1, characterized in that: One or more nucleotides in the upstream primer and the downstream primer are replaced by locked nucleic acid.

5. A kit, characterized in that: The kit comprises (i) a container and (ii) the primer-probe set according to claim 1.

6. The kit according to claim 5, characterized in that The kit further comprises a polymerase, and the polymerase is selected from the group consisting of Taq enzyme, Vent enzyme, Tth enzyme, or a combination thereof.

7. The kit according to claim 5, characterized in that The kit also includes proteinase K.

8. The kit according to claim 5, characterized in that The test kit also includes a sampling dry swab set, which includes a swab head and a swab trunk, and the swab head and the swab trunk have only two connection points.

9. A method for detecting influenza virus and monkeypox virus, characterized in that: The method comprises the following steps: (s1) providing a sample to be tested, a primer probe set as described in claim 1, and a polymerase; (s2) Under conditions suitable for amplification, using the primer probe set to perform nucleic acid amplification on the sample to be tested under the action of a polymerase, and detecting the fluorescent signal to obtain a test result.

10. The method according to claim 9, characterized in that The sample to be tested is treated with proteinase K.